Salvage external beam radiotherapy for locally recurrent prostate cancer after definitive brachytherapy

Rutenberg, M.S.; Meister, Moshe; Amin, Pradip; Hussain, Arif; Naslund, Michael J.; Kwok, Young

doi:10.1016/j.brachy.2016.08.004

Cited by 19 publications

(13 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our excellent rates of GU and GI side effects confirm the good profile of toxicity reported also by other investigators in smaller series. 17,18,20,21,23,25 For example, Leroy et al 20 in a series of 23 patients treated with SBRT (36 Gy in 6 fractions) did not observe Grade 4 or 5 toxicity. Importantly, in our series no patient experienced urinary incontinence, a typical complication of other salvage local therapies.…”

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

Reirradiation for isolated local recurrence of prostate cancer: Mono-institutional series of 64 patients treated with salvage stereotactic body radiotherapy (SBRT)

Jereczek‐Fossa

Rojas

Zerini

et al. 2019

BJR

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 98%

“…7,12 As far as reirradiation is concerned, the vast majority of patient series were treated with brachytherapy (BRT). In the last years, along with the improvement in radiotherapy (RT) planning and delivery technology, several reports on salvage EBRT have been published [14][15][16][17][18][19][20][21][22][23][24][25][26][27] (Table 1).…”

mentioning

confidence: 99%

Reirradiation for isolated local recurrence of prostate cancer: Mono-institutional series of 64 patients treated with salvage stereotactic body radiotherapy (SBRT)

Jereczek‐Fossa

Rojas

Zerini

et al. 2019

BJR

View full text Add to dashboard Cite

“…Yutkin et al. published the only series of S‐HIFU after brachytherapy demonstrating feasibility (Table ) .…”

Section: Discussionmentioning

confidence: 99%

“…Salvage therapies after brachytherapy are much less studied than those after external beam radiotherapy (EBRT) . After brachytherapy, salvage therapies, including salvage radical prostatectomy (SRP) , cryotherapy , new irradiation (brachytherapy and EBRT ), are applied in carefully selected patients and remain challenging procedures with high morbidity. Treatment options should be carefully discussed with patients given potential post‐treatment permanent side‐effects.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Salvage high‐intensity focused ultrasound for locally recurrent prostate cancer after low‐dose‐rate brachytherapy: oncological and functional outcomes

et al. 2019

View full text Add to dashboard Cite

Objectives To evaluate the oncological and functional outcomes of salvage high‐intensity focused ultrasound (S‐HIFU) for locally recurrent prostate cancer after low‐dose‐rate (LDR) brachytherapy. Patients and Methods Clinical phase II studies (2003–2015) included 50 consecutive patients with post‐brachytherapy local recurrence treated by S‐HIFU. S‐HIFU was performed with post‐external beam radiotherapy (EBRT) parameters and, since 2008, with specific post‐brachytherapy parameters. Treatments were whole‐gland ablation and, since 2009, hemi‐ablation in cases of unilateral prostate cancer. The primary objective was to assess oncological outcomes: treatment failure‐free survival, progression‐free survival (PFS), overall survival (OS), cancer‐specific survival (CSS), and metastasis‐free survival (MFS) rates. The secondary objective was to evaluate adverse events, continence, and erectile function. Kaplan–Meier analysis estimated oncological outcomes. Results In all, 13 patients were treated with post‐EBRT parameters, 37 with post‐brachytherapy parameters, 35 with whole‐gland treatment, and 15 with hemi‐ablation. The median follow‐up was 4.6 years. After S‐HIFU, the median prostate‐specific antigen level was 0.3 ng/mL. At 6 years, treatment failure‐free survival, PFS, OS, CSS, and MFS rates were 41%, 45%, 93%, 98%, and 80%, respectively. Post‐brachytherapy compared with post‐EBRT parameters reduced Grade 2–3 incontinence (34% vs 62%, P = 0.015). Incontinence, bladder outlet obstruction and Grade ≥III complications were significantly reduced with hemi‐ablation compared with whole‐gland treatment (14% vs 54%, P < 0.001; 13% vs 46%, P = 0.03; 13% vs 63%, P = 0.001; respectively). Before S‐HIFU, 25 patients had a five‐item version of the International Index of Erectile Function score of ≥17, which was maintained in 48% at 12 months. Conclusion S‐HIFU for locally recurrent prostate cancer after LDR brachytherapy is associated with favourable survival rates at a price of significant morbidity. Dedicated post‐brachytherapy parameters and hemi‐ablation improve the safety of the treatment.

show abstract

High‐dose‐rate brachytherapy for prostate cancer: Rationale, current applications, and clinical outcome

et al. 2021

View full text Add to dashboard Cite

Background: High-dose-rate brachytherapy (HDR BRT) has been enjoying rapid acceptance as a treatment modality offered to selected prostate cancer patients devoid of risk group, employed either in monotherapy setting or combined with external beam radiation therapy (EBRT) and is currently one of the most active clinical research areas.Recent findings: This review encompasses all the current evidence to support the use of HDR BRT in various clinical scenario and shines light to the HDR BRT rationale, as an ultimately conformal dose delivery method enabling safe dose escalation to the prostate. Conclusion:Valid long-term data, both in regard to the oncologic outcomes and toxicity profile, support the current clinical indication spectrum of HDR BRT. At the same time, this serves as solid, rigid ground for emerging therapeutic applications, allowing the technique to remain in the spotlight alongside stereotactic radiosurgery.

show abstract

Salvage external beam radiotherapy for locally recurrent prostate cancer after definitive brachytherapy

Cited by 19 publications

References 42 publications

Reirradiation for isolated local recurrence of prostate cancer: Mono-institutional series of 64 patients treated with salvage stereotactic body radiotherapy (SBRT)

Reirradiation for isolated local recurrence of prostate cancer: Mono-institutional series of 64 patients treated with salvage stereotactic body radiotherapy (SBRT)

Salvage high‐intensity focused ultrasound for locally recurrent prostate cancer after low‐dose‐rate brachytherapy: oncological and functional outcomes

High‐dose‐rate brachytherapy for prostate cancer: Rationale, current applications, and clinical outcome

Contact Info

Product

Resources

About